Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.

Front Immunol · 2025 · PMC12417395 · PMID 40934000

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

showed a trendp = 0.076so close (0.05 < p ≤ 0.1)

Regarding tumor characteristics, the distribution of CNCL stage showed a trend toward differences (p = 0.076); stage IIa disease was observed in 25.0% of the non-recurrence group compared to 50.0% in the recurrence group, while the distribution of other stages was similar.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.